Four Korean-American Biotech Startups Pursue KOSDAQ Listings via KDR by July End

According to industry sources, four biotech startups founded by Korean scientists and based in the U.S. are pursuing KOSDAQ technology track listings on July 9. Instead of directly listing their U.S. corporations, the companies plan to issue Korean Depositary Receipts (KDR) to enter the domestic market. IngeniaTherapeutics is expected to launch its public offering subscription by end of July, marking the first KOSDAQ listing by an overseas biotech company since NeoImmuneTech in 2021.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments